- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05210530
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
June 23, 2023 updated by: CRISPR Therapeutics AG
An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
VCTX210A combination product (unit) comprises 2 components: (1) allogeneic pancreatic endoderm cells (PEC210A) genetically modified using Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) to promote immune evasiveness and survival, and (2) a durable, removable, perforated device designed to deliver and retain the PEC210A cells.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada
- University of Alberta
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- University of British Columbia
-
-
Ontario
-
Toronto, Ontario, Canada
- LMC Manna
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Diagnosis of T1D for a minimum of 5 years
- Stable, optimized diabetic regimen for at least 3 months prior to enrollment
Exclusion Criteria
- Medical history of islet cell, kidney, and/or pancreas transplant
- Occurrence of 2 or more severe, unexplained hypoglycemic events within 6 months prior to enrollment
- Known causes of diabetes other than T1D
- Immunosuppressant therapy in the previous 30 days and/or requirements for chronic immunosuppressive therapy during the study
- Prior treatment with gene therapy or edited product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VCTX210A combination product
Up to seven (7) units will be implanted
|
CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events with causality related to VCTX210A units and/or the surgical procedures required to implant and explant the VCTX210A units.
Time Frame: From implantation up to 6 months post implantation
|
From implantation up to 6 months post implantation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Qualitative evaluation of immune response to VCTX210A units assessed by histological staining for markers of host innate immune cells within the graft.
Time Frame: From implantation up to 6 months post implantation
|
From implantation up to 6 months post implantation
|
Qualitative evaluation of immune response to VCTX210A units assessed by histological staining for markers of host adaptive immune cells within the graft.
Time Frame: From implantation up to 6 months post implantation
|
From implantation up to 6 months post implantation
|
Incidence of new alloreactive antibodies found in the blood of patients post implantation.
Time Frame: From implantation up to 6 months post implantation
|
From implantation up to 6 months post implantation
|
Incidence of new autoreactive antibodies found in the blood of patients post implantation.
Time Frame: From implantation up to 6 months post implantation
|
From implantation up to 6 months post implantation
|
The percentage of viable graft cells per unit using immunohistochemical staining.
Time Frame: From implantation up to 6 months post implantation
|
From implantation up to 6 months post implantation
|
The percentage of graft cells per unit that have differentiated into endocrine/beta cells as determined by immunohistochemical staining.
Time Frame: From implantation up to 6 months post implantation
|
From implantation up to 6 months post implantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Manasi Jaiman, MD, MPH, ViaCyte
- Study Director: Sandeep Soni, MD, CRISPR Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 24, 2022
Primary Completion (Actual)
January 19, 2023
Study Completion (Actual)
January 19, 2023
Study Registration Dates
First Submitted
December 7, 2021
First Submitted That Met QC Criteria
January 18, 2022
First Posted (Actual)
January 27, 2022
Study Record Updates
Last Update Posted (Actual)
June 26, 2023
Last Update Submitted That Met QC Criteria
June 23, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VCTX210A-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Metabolism Disorders
-
University of AberdeenCompletedMetabolism Disorder, GlucoseUnited Kingdom
-
Columbia UniversityCompletedMetabolism Disorder, GlucoseUnited States
-
University of LeipzigInstitut für Gesundheits- und Praxismanagement GmbHWithdrawn
-
Purdue UniversityAlmond Board of CaliforniaActive, not recruitingGlucose Intolerance | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
University of Missouri-ColumbiaCompletedGlucose | Blood Sugar; High | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
University of South CarolinaCompletedPhysical Activity | Sedentary Lifestyle | Metabolism Disorder, GlucoseUnited States
-
Solvay PharmaceuticalsTerminatedDyslipidemia | Glucose Metabolism DisorderPoland, Croatia, Finland, France, Germany, Netherlands, Romania, Ukraine
-
DLR German Aerospace CenterCompletedGlucose Metabolism Disorders | Local Glucose Uptake
-
Solvay PharmaceuticalsCompletedDyslipidemia/Glucose Metabolism DisorderPoland, Ukraine, United Kingdom
-
Solvay PharmaceuticalsCompletedDyslipidemia/Glucose Metabolism DisorderCzech Republic, France, Hungary, India, Lithuania, Poland, Slovakia
Clinical Trials on VCTX210A unit
-
Ostfold Hospital TrustUniversity of TromsoCompletedLow Risk Birth; Births With Low Risk FactorNorway
-
Liberating Technologies, Inc.Vivonics, Inc.CompletedLower Limb Amputation Below Knee (Injury) | Amputation | Prosthesis User | Amputation; Traumatic, Leg, Lower | Limb; Absence, Congenital, Lower | Amputation StumpUnited States
-
Mayo ClinicCompletedPostoperative PainUnited States
-
Centre Hospitalier St AnneAssistance Publique - Hôpitaux de Paris; Ministry of Health, FranceRecruiting
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
Universidad de LeónActive, not recruiting
-
The University of Tennessee, KnoxvilleCompleted
-
Virginia Commonwealth UniversityRecruitingFunctional Gastrointestinal DisordersUnited States
-
Velico MedicalRecruiting
-
University Hospital, ToulouseCompleted